Key result
Direct oral anticoagulants are increasingly recommended in modern guidelines for the prevention and treatment of cancer-associated thrombosis, offering an effective alternative to low-molecular-weight heparins.
Why the study?
Cancer-associated thrombosis carries increased mortality and treatment delays, prompting an evaluation of direct oral anticoagulants in prophylaxis and treatment alongside updated guideline recommendations and potential risks.
Does direct oral anticoagulants improve prevention and treatment of venous thromboembolism in patients with cancer-associated thrombosis?
Does direct oral anticoagulants improve prevention and treatment of venous thromboembolism in patients with cancer-associated thrombosis?
DOACs are increasingly recommended in clinical guidelines for the prevention and treatment of cancer-associated thrombosis, allowing for a more personalized and effective approach.
DOACs should inform CAT management to avoid treatment delays; extends guidelines with newest recommendations for clinicians and researchers.
Patients with malignancy have higher risk of developing cancer-associated thrombosis (CAT), with predominance of venous thromboembolism (VTE). CAT in these patients leads to the delay of specific cancer treatment, worse treatment outcomes and also increased mortality rates. This article is evaluating the role of direct oral anticoagulants (DOAC) in the prophylaxis and treatment of VTE in patients with CAT. The review shed the light on the newest recommendations and guidelines, according to the newest treatment guidelines, but it also discusses the potential risks of DOAC therapy in patients with CAT. Compared to the previous recommendations, in the latest clinical guidelines for the prevention and treatment of CAT, DOAC are becoming more important. However, considering that cancer patients represent a highly specific group of patients, diversification and expansion of CAT anticoagulant therapy provides personalized approach to each patient achieving more efficient and safer profile of anticoagulant therapy.
No takes yet. Share an insight, caveat, or question.
Antić et al. (2022) conducted a review in Cancer-associated thrombosis (CAT) and venous thromboembolism (VTE). Direct oral anticoagulants (DOACs) vs. Low-molecular-weight heparins (LMWH) or Vitamin K antagonists (VKA) was evaluated. Direct oral anticoagulants are increasingly recommended in modern guidelines for the prevention and treatment of cancer-associated thrombosis, offering an effective alternative to low-molecular-weight heparins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: